These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24903436)

  • 1. Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease.
    Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2014 Jul; 40(1):120-1. PubMed ID: 24903436
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.
    Levesque BG; Feagan BG
    Aliment Pharmacol Ther; 2014 Jul; 40(1):121-2. PubMed ID: 24903437
    [No Abstract]   [Full Text] [Related]  

  • 3. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
    Levesque BG; Greenberg GR; Zou G; Sandborn WJ; Singh S; Hauenstein S; Ohrmund L; Wong CJ; Stitt LW; Shackelton LM; King D; Lockton S; Ducharme J; Feagan BG
    Aliment Pharmacol Ther; 2014 May; 39(10):1126-35. PubMed ID: 24689499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
    Kume K; Yamasaki M; Yoshikawa I; Harada M
    Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasma ghrelin following infliximab in Crohn's disease.
    Sung EZ; Da Silva NF; Goodyear S; McTernan PG; Sanger GJ; Nwokolo CU
    Aliment Pharmacol Ther; 2009 Jan; 29(1):83-9. PubMed ID: 18793341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: is CRP ready for use to indicate response or remission with infliximab in Crohn's?
    Card T
    Aliment Pharmacol Ther; 2012 Apr; 35(8):960-1; discussion 961-2. PubMed ID: 22436039
    [No Abstract]   [Full Text] [Related]  

  • 8. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines].
    Chanson P; Pariente A
    Rev Prat; 2015 Apr; 65(4):473. PubMed ID: 26058185
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 14. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W; Wang Y; Oddens BJ; Link R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.